Immunic announced that it has received a notice of allowance from the United States Patent and Trademark Office, or USPTO, for patent application 16/981,122, entitled, “Calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferative agents,” covering the composition-of-matter of a specific polymorph of vidofludimus calcium and a related method of production of the material. The claims are expected to provide protection into 2039, unless extended further. The patent was previously granted to the company in Australia, Canada, Indonesia, Japan and Mexico.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
